natgillin/translations-raw huggingface dataset:
A magnetic drive according to any one of Claims 1-12 further comprising an electric motor disposed outside the food-contact chamber and mechanically coupled to the driving member. 
Magnetni pogon prema bilo kojem od patentnih zahtjeva 1-11, naznačen time što nadalje sadrži elektromotor smješten izvan komore za kontakt s hranom i mehanički spojen na pogonski element.
The pharmaceutical composition of claim 9, wherein the divalent or trivalent cation is magnesium. 
Aerosol za uporabu sukladno patentnim zahtjevima 1 do 4, pri čemu je koncentracija dvovalentnog ili trovalentnog kationa 200 mM.
The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula: 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol, pri čemu je tvar tvar formule:
A PDE7 inhibitor for use in treating a movement abnormality associated with the pathology of a neurological disorder in a patient in need thereof which PDE7 inhibitor is one of the following formulas: formula 6E; formula 6F; formula 6G; or formula 6H, or a pharmaceutically acceptable salt thereof. 
HR P20181608 T1 PATENTNI ZAHTJEVI 1. -oInhibitor PDE7 namijenjen upotrebi u liječenju abnormalnosti kretanja povezanog s patologijom neurološkog poremećaja u bolesnika kojem je takvo liječenje potrebno, naznačen time, da inhibitor PDE7 ima jednu od sljedećih 5
The press-on portion 15 preferably consists of an elastic material, and more particularly a material, which as such is more flexible than the material of the lock-up body 14. 
- sastoji se od elastičnog materijala koji je kao takav mnogo fleksibilniji od materijala tijela za zaključavanje(14), koji, poželjno posredstvom koekstruzije, je načinjen u jednom dijelu s tijelom za zaključavanje (14);
An antimicrobial composition comprising a siliceous sorbent and a medicinal agent immobilized thereon, characterized in that the siliceous sorbent is pyrogenic silica and the medicinal agent is serrathiopeptidase, both present in the following amounts, % by weight: 
PATENTNI ZAHTJEVI Antimikrobni sastav koji sadrži silikatni sorbent i medicinsko sredstvo imobilizirano na njemu, naznačen time, da silikatni sorbent je pirogeni silicij i medicinsko sredstvo je seratiopeptidaza, oboje prisutno u sljedećim količinama masenih postotaka: pirogeni silicij
The reaction was stirred under an atmosphere of nitrogen overnight at 95°C. 
Reakcija se miješa u atmosferi dušika preko noći na 95%C.
The AvPAL variant of claim 5, wherein the AvPAL variant is obtainable by reacting AvPAL variant with NHS-activated polyethylene glycol at a ratio of 3 polyethylene glycol per lysine residue of the AvPAL variant. 
AvPAL varijanta u skladu s patentnim zahtjevom 5, naznačena time, da se može dobiti reakcijom AvPAL varijante s polietilen glikolom aktiviranim NHS-om u omjeru 3 polietilenglikola po ostatku lizina AvPAL varijante.
The combined organic phases were washed with brine, dried over sodium sulfate and concentrated under reduced pressure. 
Pomiješane organske faze ispere se slanom vodom, osuši preko natrijevog sulfata, te koncentrira pod sniženim tlakom.
Feature 15. A process according to feature 14, wherein R1 is benzyl and in step (j) the benzyl group is removed in situ by reaction with trifluoroacetic acid at a temperature in the range of from 60 to 80°C. 
Postupak prema zahtjevu 6, naznačen time, da R' je benzil, a u koraku (i) se benzilna skupina odstranjuje in situ pomoću reakcije sa trifluorooctenom kiselinom na temperaturi u rasponu od 60 do 80% C. 8.
A method for producing a carbamylated erythropoietin protein having less than about 3% aggregated protein and less than about 40% by weight of over- and under-carbamylated protein as measured by ESI-mass spectrometry, comprising purifying the carbamylated erythropoietin using anion exchange, cation exchange, hydrophobic interaction chromatography, reverse phase chromatography, affinity chromatography or size exclusion chromatography. 
Postupak za proizvodnju karbamiliranog proteina eritropoetina koji ima manje od oko 3% nagomilanog proteina i manje od oko 40 te2.% prekomjerno- i premalo-karbamiliranog proteina kao što je mjereno pomoću ESI- spektrometrije mase, naznačen time što sadrži pročišćavanje karbamiliranog eritropoetina primjenom anionsko izmjene, kationske izmjene, kromatografije zasnovane na hidrofobnim interakcijama, reverzno fazne kromatografije, afinitetne kromatografije ili ekskluzione kromatografije, tr>
The building block of claim 1, characterized in that the static insert structure (2) is made from cylindrical plastic tubes or from organic material, preferably from wood. 
Građevinski blok prema zahtjevu 1, naznačen time što je statična uložna struktura (2) napravljena od organskog materijala.
The extrudate of claim 6, wherein the structured soy protein extrudate has been subjected to freezing prior to infusion. 
Postupak skladno patentnom zahtjevu 7, naznačen time, da je ekstrudat strukturiranog biljnog proteina podvrgnut smrzavanju prije infuzije.
Garment, according to claim 1, characterized in that the content of polyurethane covering the synthetic fibres is in the range of 0,1% and 0,3% in weight. 
Odjevni predmet u skladu s patentnim zahtjevom 1, naznačen time, da je sadržaj poliuretana koji prekriva sintetička vlakna u rasponu od 0,1 % do 0,3 % težine u odnosu na ukupnu težinu odjeće.
The compounds of the invention for use in: 
Datum objave europskog patenta:
a water tank; a percolation element; 
spremnik za vodu (2); element za cijeđenje (6);
The flask was placed in an ice/water bath and the solution was stirred for 15 minutes. 
Tikvica je bila stavljena u kupelj led/voda i otopina je bila miješana 15 minuta.
Each bush portion is defined by a substantially curved profile 6 on the outer side surface of the core 1. 
Svaka čahura odlikuje se izrazito zakrivljenim profilom 6 na vanjskoj strani površine jezgre 1.
Next, 3,3-dimethoxy-1-propene (2.03g, 17.7mmol) followed by CSA (0.035g, 0.15mmol) were added to the solution. 
Nakon toga je dodan 3,3-dimetoksi-1-propan (2.03 g, 17.7 mmol), zatim CSA (0.035 g, 0.15 mmol), u otopinu.
Figure 10 illustrates that rapamycin induces platelet aggregation in a dose dependent manner. 
Slika 10 pokazuje da rapamicin inducira agregaciju trombocita ovisno o dozi.
The combined organic extracts were dried (Na2SO4), filtered and concentrated to obtain intermediate 26 (1.19 g, 24% over three steps) as brownish oil: LC/MS m/z 299 (M+H). 
Kombinirani organski ekstrakti su sušeni (Na,SOx), filtrirani i koncentrirani da bi se dobio Intermedijer 26 (1.19 g, 24% u tri koraka) kao smećkasto ulje: LC/MS m/z 299 (M+H).
a control head (120) adapted to determine a temperature and a pressure of said primary heating liquid; 
(54) Naziv izuma: = ELEKTRIČNI SISTEM ZA ZAGRIJAVANJE, KONTROLNA GLAVA I TEKUĆINA ZA ZAGRIJAVANJE HR P20190743 T1
The process of any one of claims 1-12, wherein the color of the solution of hydrobromic acid in acetic acid is less than 2000 APHA. 
Postupak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da otopina bromovodične kiseline u octenoj kiselini jest 10%-36%-tna bromovodična kiselina u octenoj kiselini.
A method as claimed in claim 8 wherein data points in the driver profile are, for at least one profile index, classified against a plurality of possible values for the profile index, and wherein deriving the analysis profile comprises selecting data points corresponding to a subset of possible values of the profile index. 
9. Postupak prema zahtjevu 8, naznačen time da su podatkovne točke u vozačevom profilu, barem u jednom indeksiranom profilu, određene mnoštvom mogućih vrijednosti indeksiranog profila 1 pri čemu deriviranje analitičkog profila sadrži odabir podatkovinh točki koje odgovaraju podskupu mogućih vrijednosti indeksiranog profila.
According to another aspect of the invention, there is provided the use of a compound of formula (I) or a physiologically acceptable solvate thereof for the manufacture of a medicament for the treatment of patients with inflammatory and/or allergic conditions. 
Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 5, naznačen time što upalno i/ili alergijsko stanje je astma.
An ex vivo method for producing platelets, comprising a step of subjecting a suspension of cells comprising mature megakaryocytes to a flow permitting exposure to a shear rate sufficient for platelet generation, on a solid phase coated with Von Willebrand factor (VWF) or a fragment or variant thereof which binds to GPIb thereby forming platelets. 
HR P20160404 T1 PATENTNI ZAHTJEVI 1. Ex vivo metoda za proizvodnju trombocita, obuhvaća korak podvrgavanja suspenzije zrelih megakariocita protoku dozvoljavajući izlaganje naprezanju odgovarajućem za stvaranje trombocita i na čvrstoj fazi oblaganje Von Willebrandovim faktorom (VWEF), ili njegovim fragmentom ili inačicom ili analogom, koji veže GPIb.
The liquid components were dosed stepwise, subsequently to the solid components: at first KOH for about 2 minutes and then orthophosphoric acid for 6 minutes at 250 to 300 rev./min. 
Tekuće komponente se postepeno doziraju za čvrstim komponentama: najprije KOH, što traje pribl. 2 minute i zatim ortofosforna kiselina, 6 minuta, uz miješanje s 250 do 300 okretaja u minuti.
Dc 1.515g.cm-1 the same X-ray powder diffraction (XRPD) pattern as a) or b) post storage at 40°C and 75% RH for at least a week; or 
isti spektar difrakcije X-zraka praha (XRPD) kao što su (a) ili (b), poslije barem tjedan dana skladištenja na 40°C i 75% RV; ili
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, cell biology, immunology and pharmacology, within the skill of the art. 
Praksa ovog izuma koristit će, ukoliko nije drukčije naznačeno, uobičajene postupke kemije, biokemije, molekularne biologije, stanične biologije, imunologije i farmakologije, u skladu s praksom struke.
In certain embodiments, the prepared fuel product may comprise a fluidized catalytic cracker product composition derived from catalytic contact of a feedstock comprising a renewable fuel oil, for example a fuel composition derived from a petroleum fraction feedstock, and a renewable fuel oil feedstock, such as a fuel composition derived from 80-99.95 wt. 
Postupak proizvodnje goriva, koji sadrži: ko-procesiranje sirovine u prisutnosti katalizatora, gorivo sadrži proizvod fluidiziranog katalitičkog krekera koji ko-procesira sirovinu, navedena sirovina sadrži: i) 80-99,95 wt.
In the next day, 100 ul of goat anti-rabbit IgG diluted 1:20 and 100 ul of normal rabbit serum diluted 1:1000 are added and the mixture incubated for another 3 hr at room temperature. 
Sljedećeg dana dodano je 100 ul kozjeg protukunićjeg IgG razrijeđenog 1:20 1 100 ul normalnog kunićjeg seruma razrijeđenog 1:1000, a smjesa je inkubirana još 3 sata na sobnoj temperaturi.
A container according to any of the preceding claims, wherein the access aperture of the inner package is defined by one or more lines of weakness in the inner package. 
Spremnik (600) prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je pristupni otvor unutrašnjeg pakiranja (606) definiran s jednom ili više linija oslabljenja u unutarnjem pakiranju (606).
The mice are also a suitable model for ischemic heart disease [Matsuda, M et al. J Biol Chem (2002) July, and references cited therein, the disclosures of which are incorporated herein by reference in their entirety]. 
Miševi su također prikladan model za ishemijsko srčano oboljenje [Matsuda, M et al, J Biol Chem (2002) July, te zabilješke u navedenom, sadržaj čega je u potpunosti ugrađen u ovaj tekst u potpunosti].
The process according to claim 1, wherein the formylating agent in step 4 is selected from the group consisting of DMF, 1-formyl-piperidine, 1-formyl piperazine, N-methyl-N-(2-pyridyl) formamide, N-methyl formanilide, and Weinreb formamide. 
Postupak u skladu s bilo kojim navedenim zahtjevom naznačen time da se formilirajući agens u koraku 4 odabere iz skupine koja se sastoji do DMF, 1-formil-piperidina, 1-formil-piperazina, N-metil-N-(2-piridil)-formamida, N-metil-formanilida, Weinrebovog formamida.
when they are one-dimensional, the said flexible elements comprise a plurality of rectilinear parallel rods (52) 
- kada su jednodimenzijski, navedeni fleksibilni elementi sadrže više pravocrtnih paralelnih štapova (52);
Fig. 2 shows an exemplary embodiment of a method according to the invention. 
Slika 2 prikazuje primjer izvedbe postupka prema izumu.
the spacer (1) having a principal axis of rotation (4) running in the axial direction (z), 
- < gdje razmaknica (1) ima glavnu os vrtnje (4), koja ide u smjeru osi (z),
mixing a first prepolymer mixture of mass A and a second prepolymer mixture of mass B, said first prepolymer mixture comprising a first polycaprolactone having preferably molecular weight of 200 to 6000, and X wt% free diphenylmethane diisocyanate, and said second prepolymer mixture comprising a second polycaprolactone having preferably molecular weight of 200 to 6000, and Y wt% free diphenylmethane diisocyanate, and wherein A, B, X and Y are selected such that (A X+ B Y)/(A + B) is from 2.0 to 5.0; and curing the mixed first and second prepolymer mixtures with a chain extender to form said polyurethane elastomer. 
Postupak za izradu poliuretanskog elastomera, naznačen time, da se sastoji od: miješanja prve smjese predpolimera mase A i druge smjese predpolimera mase B, dok navedena prva smjesa predpolimera sadrži prvi polikaprolakton koji po mogućnosti ima molekularnu masu od 200 do 6000, i X masenih % slobodnog difenilmetan diizocijanata, a navedena druga smjesa predpolimera sadrži drugi polikaprolakton koji po mogućnosti ima molekularnu masu od 200 do 6000, i Y masenih % slobodnog difenilmetan diizocijanata, i gdje su A, B, X i Y odabrani tako da (AX-+BY)/(A+B) je od 2,0 do 5,0; i stvrdnjavanja miješanih prvih i drugih smjesa predpolimera sa produživačem lanca da oblikuju navedeni poliuretanski elastomer.
The compound of claim 22-24, wherein Rq is H or fluoro. 
Spoj prema patentnim zahtjevima 22 do 24, naznačen time, da Rq je H ili fluoro.
the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, 
kod subjekta (i) nije došlo do 1,5 puta većeg ili još većeg porasta kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine, (ii) izdaje mokraću u količini od najmanje 0,5 ml/kg na sat tijekom 6 sati prije vremena kada je uzet uzorak tjelesne tekućine, a kod (iii) nije došlo do porasta od 0,3 mg/dl ili većeg kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine,
In short, glycogen phosphorylase has been implicated in the regulation of excessive hepatic glucose production - a significant contributor to diabetic hyperglycemia. 
Ukratko, glikogen-fosforilaza uključena je u regulaciju prevelike jetrene proizvodnje glukoze - značajnog doprinositelja dijabetičkoj hiperglikemiji.
Separate dosage forms or a package according to any of claims 7-9, wherein said second agent is for simultaneous administration. 
Posebni dozirni oblici ili pakiranje prema bilo kojem od zahtjeva 11-13, gdje je drugo sredstvo za istodobnu primjenu.
Use of a compound according to claim 1, a salt thereof or a hydrate of the foregoing, for the preparation of a medicament for inhibiting angiogenesis. 
Uporaba spoja prema zahtjevu 1, njegove soli ili hidrata, naznačena time da je za pripremu lijeka za inhibiciju angiogeneze.
an end of state B until a beginning of a next state A; 
kraja stanja B do početka narednog stanja A;
The compound of claim 1, wherein the compound has the structure: wherein Xa is selected from methyl, methoxy, CH2OH and CH2F. 
ko: XS naznačeno time, što je X* odabran iz metila, metoksija, CH2OH i CHLF.
A container for storing and/or administering a vaccine composition, wherein the container contains a vaccine composition comprising an Hepatitis B antigen adsorbed on an aluminum oxyhydroxide adjuvant and is closed by a device acting as a stopper, wherein the surface of the device contactable with the composition is coated with a fluoropolymer. 
PATENTNI ZAHTJEVI M» Spremnik za pohranjivanje i/ili davanje pripravka cjepiva, pri čemu spremnik sadrži pripravak cjepiva koji sadrži antigen Hepatitisa B adsorbiran na adjuvantu aluminijevog oksihidroksida i zatvoren je s uređajem koji djeluje kao čep, naznačen time da je površina uređaja koja dolazi u kontakt s pripravkom obložena fluorpolimerom.
at least one steam boiler hose (9) which conveys the water in the water tank (5) to the steam boiler (8), 
barem jednu cijev za parni kotao (9) koja provodi vodu iz spremnika za vodu (5) do parnog kotla (8),
A compound according to claim 1 wherein R1 is R1a and R2 is R2a and R1a and R2a are each selected from hydrogen, methyl, methoxymethyl and allyl. 
Spoj prema zahtjevu 1 naznačen time da R1 je R1a a R2 je R2a te da su i R1a i R2a odabrani iz skupine koju čine vodik, metil, metoksimetil i alil.
Albumin binding peptide-Fab compounds of the invention: 
Broj objave europskog patenta:
The method of claim 6, wherein the substage of setting a control algorithm of the state of charge of the energy storage system uses a deadband or hysteresis to limit the activation conditions of this algorithm to deviations from the target SOC which are great enough. 
Postupak kontrole rampi fluktuiranja snage sustavima za pohranu energije u elektranama za intermitentno generiranje snage u skladu s patentnim zahtjevom 8, naznačen time što podstadij namještanja algoritma kontrole stanja napunjenosti sustava za pohranu energije upotrebljava mrtvi pojas ili histerezu kako bi se ograničilo aktiviranje uvjeta tog algoritma na devijacije od ciljanog SOC koje su dovoljno velike.
Magnesium Stearate 10.0 and the third layer comprises 150 ± 8.0 mg of microcrystalline cellulose or lactose monohydrate, or a mixture thereof. 
Tableta zahtjeva 12 gdje se prvi sloj sastoji od: [image] drugi sloj se sastoji od: [image] a treći sloj sadrži 150 ± 8.0 mg mikrokristalne celuloze ili laktoza monohidrata, ili njihove miksture.
Thereby it is useful for the strap and the main body of the inhaler to be manufactured from the same material. 
Zbog toga je zgodno ako su vrpca i glavno tijelo inhalatora načinjeni od istog materijala.
At a suitable temperature, the wax melts, thereby liberating ceramic or glass particles to adhere to the surface of the container as well as the surface of the retainer 34 . 
614). koji se u najmanju ruku dijelom nalazi u unutarnjem prolazu grla spremnika, te uključuje najmanje jednu keramičku ili staklenu komponentu (34, 134, 234.
which is reacted in a continuous oxidation followed by a quench reaction to prepare Compound C of the formula and protecting to convert Compound C to Compound D of the formula 
HI no ha zi mm Spoj B b) koji reagira u kontinuiranoj oksidaciji nakon čega slijedi reakcija gašenja radi pripreme Spoja C formule 25
A pharmaceutical composition comprising the compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži spoj prema zahtjevu 1 ili zahtjevu 2 i farmaceutski prihvatljiv nosač.
A compound of formula (XII): wherein X is selected from the group consisting of Cl, Br and I; wherein R′ is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R′ is trimethylsilyl and R is tert-butoxycarbonyl; or R and R′ taken together with the nitrogen atom they are linked to form a phthalimido group. 
Postupak iz patentnog zahtjeva 8, naznačen time da je R odabran iz sljedeće skupine: benzil, acetil, benzoil, trifluormethanesulfonil, benzenesulfonil, p-toluensulfonil, metoksikarbonil, etoksikarbonil, ferf-butoksikarbonil, aliloksikarbonil, benziloksikarbonil. HR P20130978 T1 Postupak iz patentnog zahtjeva 7, naznačen time da u spoju formule (VI) R' jest tri(C;-C; alkil)silil, a R jest C;-C alkoksikarbonil ili benziloksikarbonil koji je na aromatskom prstenu supstituiran s do tri supstituenta odbranih od sljedećih: halogen, cijano 1 trifluometilna skupina.
assaying the amplified fragments of the one or more DNA markers to detect plant seed contamination of normal fertile plant seeds among cytoplasmic male sterile plant seeds of an inbred line of sunflower plant crop having a cytoplasmic or nuclear-cytoplasmic system of male sterility; 
(c) analize pojačane kloroplasne DNA koja sadrži jedan ili više DNA markera za detekciju biljnog sjemena kontaminacija normalnih plodnih biljnih sjemenki među citoplazmatskim muškim sterilnim biljnim sjemenkama zrna biljke usjeva koji ima citoplazmatski ili nuklear-citoplazmatski sustav muške sterilnosti.
This term relates IL-18 binding proteins such as the ones defined in WO 99/09063 or in Novick et al., 1999. 
Ovaj pojam se odnosi na vezne proteine IL-18 poput onih koji su definirani u patentu WO 99/09063 ili u radu Novick i sur., 1999.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
The challenge has thus been to achieve that metal packaging will be able to “act” like or emulate a plastic packaging in the automated packing machines, e.g. that the metal packaging may be opened like a book with an angle of more than 180°, preferably 240°. 
Prema tome je bio izazov postići to, da metalno pakiranje "radi" kao plastično pakiranje ili da se takmiči s njim u automatiziranim strojevima za pakiranje, na primjer, da se metalno pakiranje može otvoriti kao knjiga pod kutom koji je veći od 180" poželjno 240
manufacturing a preparation of the modular antibody. Method according to claim 11, which further comprises the step of affinity maturation of said library member. Modular antibody according to any of claims 1 to 10, for treating a patient suffering from a solid tumor, which tumor expresses a receptor of the erbB class. 
Modularno protutijelo prema bilo kojem od zahtjeva 1 do 8 ili 12 do 13, ili molekula protutijela prema bilo kojem od zahtjeva 9 do 11, naznačeno/naznačena time, da se upotrebljava u liječenju pacijenta koji boluje od čvrstog tumora, pri čemu tumor izražava receptor iz erbB-razreda.
Another object of the invention is a novel type of compounds, derivatives of dianhydrohexite mononitrate, which are capable of providing a potent antithrombotic effect even at a dose that does not modify the blood pressure. 
Drugi predmet izuma je novi tip spojeva, derivati dianhidroheksit mononitrata, koji mogu osigurati jaki antitrombozni učinak čak pri dozi koja ne modificira krvni tlak.